Abstract
Introduction
Impaired left ventricular (LV) diastolic relaxation, detected by pulsed Doppler echocardiography, is predictive of a higher incidence of major cardiovascular events in hypertensive patients. An improvement in LV diastolic function is an important goal of treatment. However, treatment of LV diastolic dysfunction remains empirical. The objective of our study was to compare the short-term effects of nebivolol and atenolol on Doppler diastolic filling parameters in hypertensive patients.
Methods
A total of 32 patients with mild-to-moderate hypertension were enrolled in the study. The patients were randomly assigned to receive treatment with either nebivolol (5 mg/day) or atenolol (50 mg/day) for 1 month. Diastolic filling parameters, with pulsed-wave Doppler transmitral flow velocities, were measured 1 day before and 1 month after treatment.
Results
Compared with baseline, both agents significantly decreased heart rate and blood pressure. However, there was no significant difference in pre-and post-treatment values between the nebivolol and atenolol groups. Both drugs significantly improved LV transmitral flow measured by early diastolic flow/atrial contraction signal (E/A) ratio, decreased deceleration time (DT) and isovolumetric contraction time (IVRT), but post-treatment improvement in E/A, DT and IVRT values was more significant with nebivolol compared with atenolol (P=0.05, P=0.05 and P=0.003, respectively).
Conclusions
Although treatment with nebivolol or atenolol results in improved LV transmitral diastolic function filling parameters (E/A ratio, IVRT and DT), nebivolol has a greater effect compared with atenolol in patients with mild-to-moderate hypertension.
Similar content being viewed by others
References
Murray CJ, Lopez AD. Evidence-based health policy — lessons from the Global Burden of Disease Study. Science. 1996;274:740–743.
European Study Group on Diastolic Heart Failure. How to diagnose diastolic heart failure. Eur Heart J. 1998;19:990–1003.
Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol. 1995;26:1565–1574.
Graettinger WF, Bryg RJ. Left-ventricular diastolic dysfunction in hypertension. Curr Opin Cardiol. 1994;9:551–560.
Schillaci G, Pasqualini L, Verdecchia P, et al. Prognostic significance of left ventricular diastolic dysfunction in essential hypertension. J Am Coll Cardiol. 2002;39:2005–2011.
Vasan RS, Benjamin EJ, Levy D. Congestive heart failure with normal left ventricular systolic function. Clinical approaches to the diagnosis and treatment of diastolic heart failure. Arch Intern Med. 1996;156:146–157.
Cleland JG. ACE inhibitors for ‘diastolic’ heart failure? Reasons not to jump to premature conclusions about the efficacy of ACE inhibitors among older patients with heart failure. Eur J Heart Fail. 2001;3:637–639.
Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: part II. Causal mechanisms and treatment. Circulation. 2002;105:1503–1508.
Bella JN, Palmieri V, Roman MJ, et al. Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle-aged and elderly adults: the Strong Heart Study. Circulation. 2002;105:1928–1933.
Mayet J, Shahi M, Poulter NR, Sever PS, Foale RA, Thom SA. Left ventricular diastolic function in hypertension: a 4 year follow-up study. Int J Cardiol. 1995;50:181–188.
McNeely W, Goa KL. Nebivolol in the management of essential hypertension: a review. Drugs. 1999;57:633–651.
Mangrella M, Rossi F, Fici F, Rossi F. Pharmacology of nebivolol. Pharmacol Res. 1998;38:419–431.
Ritter JM. Nebivolol: endothelium-mediated vasodilating effect. J Cardiovasc Pharmacol. 2001;38(suppl 3):s13–s16.
Himmelmann A, Kjeldsen SE, Hedner T. Recent hypertension guidelines. JNC-7 and 2003 ESH/ESC. Blood Press. 2003;12:196–197.
Pickering TG. Blood pressure measurement issues. In: Oparil S, Weber MA, eds. Hypertension: A Companion to Brenner and Rectors’s the Kidney. Philadelphia: WB Saunders; 2000:306–313.
Henry WL, de Maria A, Gramiak R. Report of the American Society of Echocardiography Committee on Nomenclature and Standards in two-dimensional echocardiography. Circulation. 1980;62:212–222.
Schobel HP, Langenfeld M, Gatzka C, Schmieder RE. Treatment and posttreatment effects of alpha-versus betare-ceptor blockers on left ventricular structure and function in essential hypertension. Am Heart J. 1996;132:1004–1009.
Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. JAMA. 1996;275:1507–1513.
Liu GS, Wang LY, Nueten LV, Ooms LA, Borgers M, Janssen PA. The effect of nebivolol on left ventricular hypertrophy in hypertension. Cardiovasc Drugs Ther. 1999;13:549–551.
Nodari S, Metra M, Dei Cas L. Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol. Eur J Heart Fail. 2003;5:621–627.
Kamp O, Sieswerda GT, Visser CA. Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol. 2003;92:344–348.
Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation. 2001;104:511–514.
Taddei S, Virdis A, Ghiadoni L, Sudano I, Salvetti A. Effects of antihypertensive drugs on endothelial dysfunction: clinical implications. Drugs. 2002;62:265–284.
Paulus WJ, Shah AM. NO and cardiac diastolic function. Cardiovasc Res. 1999;43:595–606.
Grassi G, Trevano FQ, Facchini A, Toutouzas T, Chanu B, Mancia G. Efficacy and tolerability profile of nebivolol vs. atenolol in mild-to moderate essential hypertension: results of a double-blind randomized multicentre trial. Blood Press. 2003;12(suppl 2):35–40.
Cosentino F, Bonetti S, Rehorik R, et al. Nitric-oxide-mediated relaxations in salt-induced hypertension: effect of chronic beta l-selective receptor blockade. J Hypertens. 2002;20:421–428.
Müller-Brunotte R, Kahan T, Malmqvist K, Edner M. Blood pressure and left ventricular geometric pattern determine diastolic function in hypertensive myocardial hypertrophy. J Hum Hypertens. 2003;17:841–849.
Van Bortel LM, de Hoon JN, Kool MJ, Wijnen JA, Vertommen CI, Van Nueten LG. Pharmacological properties of nebivolol in man. Eur J Clin Pharmacol. 1997;51:379–384.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tuncer, M., Guntekin, U., Gunes, Y. et al. Differential effects of nebivolol and atenolol on transmitral diastolic filling parameters in patients with essential hypertension. Adv Therapy 25, 619–626 (2008). https://doi.org/10.1007/s12325-008-0065-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-008-0065-3